The Hydration Pharmaceuticals (ASX:HPC) Launches Hydralyte Plus Metabolic Support; Share Price Rises 30%

Sonal Goyal

12 August 2025 11:07 AM AEST

The Hydration Pharmaceuticals (ASX:HPC) Launches Hydralyte Plus Metabolic Support; Share Price Rises 30%

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights
• HPC’s share price rose 30% to 1.3 cents per share following the launch of Hydralyte Plus Metabolic Support.
• The product is the first of two new SKUs scheduled for release in Q3 CY25, with Hydration Plus Brain Health to follow later in August.
• The new SKU enters the US prebiotics and probiotics supplements category, valued at US$840 million on Amazon in 2024.

The Hydration Pharmaceuticals Company Limited (ASX:HPC), trading as Hydralyte USA, has announced the launch of its new Hydralyte Plus Metabolic Support product, with initial sales achieved through e-commerce platforms and Amazon USA. The update saw the company’s share price rise 30% to 1.3 cents per share on Tuesday morning.

Product Overview
The Hydralyte Plus Metabolic Support SKU targets the gut health segment and functions as a functional electrolyte with a patented formulation containing prebiotics, probiotics, and postbiotics. Its key active ingredient, Akkermansia muciniphila, is known for promoting the production of GLP-1, aiding in metabolic balance, and supporting fat and carbohydrate metabolism.

This launch marks the first of two planned SKU introductions for the quarter, with the Hydration Plus Brain Health product scheduled for release later in August 2025. Both products are designed to complement HPC’s existing high-margin Liver Detox SKU, which has been a significant contributor to sales growth.

Market Positioning
The company is positioning Hydralyte Plus Metabolic Support within the prebiotics and probiotics supplements market in the United States, a sector that ranked as the fifth largest by sales volume on Amazon in 2024. The category generated US$840 million in sales through Amazon alone last year, representing a 9% increase from 2023.

HPC’s established supply partnerships have enabled the business to allocate most product innovation costs directly to opening order inventory. This approach helps preserve cash until the point of sale, aligning with the company’s streamlined operational model in the US market.

Strategic Importance
The introduction of the new SKU supports HPC’s broader strategy to expand its presence in high-margin product segments, particularly those aligned with consumer health trends in the United States. Management expects the launch to contribute positively to sales momentum and operating margins during the high-demand summer period in Q3 CY25.

The company has highlighted that the Hydralyte Plus Metabolic Support product, along with the upcoming Brain Health SKU, will build upon the success of its research and development program. This program previously led to the Liver Detox product, which remains the company’s best-selling SKU and a key driver of recent growth.

CEO Commentary
HPC Chief Executive Officer Oliver Baker stated that the launch represents progress in the company’s plan to grow revenue and operating margins in the US market. He noted that the addition of gut health and brain health products aligns with rising demand trends and is expected to enhance the company’s sales profile as it advances toward profitability targets.

The combination of product innovation, targeted market entry, and timing during peak seasonal demand is expected to influence HPC’s operational and financial performance in the second half of the calendar year.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.